Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- University of Chicago
- Study ID
- NCT01592383
- Phase
- PHASE2
- Status
- Completed
Conditions
- Malignant Peritoneal Mesothelioma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- erlotinib hydrochloride — DRUGGiven PO
Study Details
The purpose of this study is to test the drug erlotinib (erlotinib hydrochloride) in people with malignant peritoneal mesothelioma who have a specific genetic mutation in their cancer. Erlotinib has been approved by the United States Food and Drug Administration (FDA) for other cancers, but erlotinib has not been approved for malignant peritoneal mesothelioma. This research is being done because there is no current standard treatment for malignant peritoneal mesothelioma and the study doctors want to see how erlotinib affects malignant peritoneal mesothelioma.
Key Dates
- First listed
- May 7, 2012
- Start date
- Jun 30, 2012
- Status verified
- Sep 2018
- Primary completion
- Feb 28, 2017
- Completion
- Feb 28, 2017
Study Design
- Enrollment
- 2 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (enzyme inhibitor therapy)Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Objective Response Rate [ Time Frame: 1 year ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637-1470 | - |
Find similar trials in Chicago, IL
By research site
Related Studies
- A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal MesotheliomaPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Chicago, Illinois